Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer von Tsimberidou, Apostolia-Maria, Akerley, Wallace, Schabel, Matthias C, Hong, David S, Uehara, Cynthia, Chhabra, Anil, Warren, Terri, Mather, Gary G, Evans, Brent A, Woodland, Deane P, Swabb, Edward A, Kurzrock, Razelle

Volltext

P4-362: Tarenflurbil clearance is not reduced in subjects with mild or moderate hepatic impairment von Dowd, Brian, Harrison, Shuree, Woodland, Deane, Swabb, Edward, Mather, Gary

Volltext

P4-395: Inhibition of CYP2C9 by fluconazole reduces clearance and increases exposure to tarenflurbil von Swabb, Edward, Harrison, Shuree, Woodland, Deane, Belcher, Valerie, Mather, Gary

Volltext

P4-383: Tarenflurbil (MPC-7869), a selective Aβ42-lowering agent, has no significant effect on the pharmacokinetics and pharmacodynamics of warfarin von Mather, Gary, Harrison, Shuree, Woodland, Deane, Swabb, Edward

Volltext

P4-386: Exposure to tarenflurbil (MPC-7869), a selective Aβ42-lowering agent, is not affected by administration with food von Pleiman, Chris, Jackson, Mary, Woodland, Deane, Johnson, Troy, Swabb, Edward, Mather, Gary

Volltext

Practices and considerations in the development of an allogeneic cellular transplant von Nugent, Helen M, Woodland, Anne Marie, Deane, Deborah

Volltext